Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie's $1.2B Bretisilocin Acquisition

Enveric Biosciences (NASDAQ:ENVB) recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent) titled, "Halogenated psilocybin derivatives and methods of using."

Enveric's '276 patent includes claims that appear relevant to the Bretisilocin (GM-2505) molecule currently in clinical trials, which AbbVie Inc. (NYSE:ABBV) agreed to acquire from Gilgamesh on August 25, 2025, in a definitive transaction valued at up to $1.2 billion.

The Gilgamesh PGR petition specifically targets claims that may be relevant to Bretisilocin and other claims of the ‘276 patent. Enveric's '276 patent family also includes one additional issued U.S. patent, a pending U.S. application and related international patent applications in Australia, Canada, China, Europe, Japan, Mexico and South Korea. 

Practical Implications: Enveric's Pipeline Isn't Impacted

Enveric reported that the '276 patent family does not cover the pipeline of Enveric's proprietary therapeutic candidates, such as EB-003, which are protected under separate, distinct patent families. Enveric's intellectual property portfolio, including the '276 patent family, includes 26 issued U.S. patents and a total of 60 pending national and international applications covering five programs. 

Enveric's product pipeline features: 

• EB-003, a differentiated therapeutic candidate with dual agonism at 5-HT1B and 5-HT2A receptors in development for depression and anxiety; this candidate is advancing toward the filing of an investigational new drug application to begin human clinical trials 
• The EVM-401 series of small molecules discovered through its proprietary research platform 
• Three programs and related patent portfolios that have been successfully out-licensed to third parties for development.

Under those licenses, Enveric is eligible to receive aggregate upfront, development and sales milestones potentially totaling up to $205 million, plus royalties on future sales.  

"Enveric has built a diversified product pipeline and a broad intellectual property estate designed to deliver novel solutions for serious neuropsychiatric conditions," said Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences. "As major pharmaceutical companies pursue novel approaches in this field, Enveric has gained attention and is well-positioned with differentiated patented molecules, national and international patent portfolios, and multiple programs advancing toward clinical development directly and through licensees. Enveric will vigorously defend its intellectual property and take all steps necessary to maximize the value of its intellectual property for shareholders." 

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.